Long-term Kinetics of Alpha-fetoprotein in Chronic Hepatitis C Patients Treated with Direct-acting Antivirals and Possible Predictive Role of AFP Response to Treatment on Development of Hepatocellular Carcinoma

Objectives: To evaluate the post-treatment upto fourth-year kinetics of alpha-fetoprotein (AFP) in patients with chronic hepatitis C (CHC) treated with direct-acting antiviral (DAA) drugs. Materials and Methods: In this retrospective, single-center study, 182 patients (124 female, 58 male) with CHC...

Full description

Saved in:
Bibliographic Details
Published in:Viral hepatit dergisi 2021-08, Vol.27 (2), p.49-52
Main Authors: Ulaşoğlu, Celal, Erkalma Şenateş, Banu, Yapalı, Suna, Dumanoğlu, Betül, Enc, Feruze, Çolak, Yaşar, Şenateş, Ebubekir
Format: Article
Language:English
Subjects:
Antiviral drugs
Conflicts of interest
Diabetes
Ethics
Females
Genotype & phenotype
Hepatitis C
Hypertension
Laboratories
Liver cancer
Liver cirrhosis
Risk factors
Surveillance
Ultrasonic imaging
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 52
container_issue 2
container_start_page 49
container_title Viral hepatit dergisi
container_volume 27
creator Ulaşoğlu, Celal
Erkalma Şenateş, Banu
Yapalı, Suna
Dumanoğlu, Betül
Enc, Feruze
Çolak, Yaşar
Şenateş, Ebubekir
description Objectives: To evaluate the post-treatment upto fourth-year kinetics of alpha-fetoprotein (AFP) in patients with chronic hepatitis C (CHC) treated with direct-acting antiviral (DAA) drugs. Materials and Methods: In this retrospective, single-center study, 182 patients (124 female, 58 male) with CHC treated with DAA were included in the study. Biochemistry and AFP were recruited from the hospital database. The data at pre-treatment, 3rd and 48th month after the end of treatment were evaluated. Results: Of the 182 patients, mean age was 58±12 (28-76), and forty-nine (27%) had cirrhosis. At month 3, the average decline of AFP was 35.6% (0.4-97.0). Early decline of AFP
doi_str_mv 10.4274/vhd.galenos.2021.2021-5-3
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2833273971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2833273971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c214t-37edb54647469747050c358d8712f27a134b1cdb2cc992de5a718262850b01fd3</originalsourceid><addsrcrecordid>eNotUduK2zAQNaWFht39hyl9VmrdIvsxeLvd0kDDsn0WsjxOVBzJlZSU_c39oir1wjAXOMw5M6eqPtF6LZgSXy7HYX0wE_qQ1qxm9H8ikvB31YpRoQhrefu-WlFeK9IKQT9Wdym5vhZCbYRUclW97oI_kIzxBD-cx-xsgjDCdpqPhoyYwxxDRuehRHeMwTsLjzib7LJL0MG-dOhzgueIJuMAf10-wr2LaDMxNjt_gK3P7uKimRIYP8A-XDVMCPuIgyuQC8JTKPOV92EPT5jm4BNCDsvWUyGA4OEeLziFeRnHRUawOE3nyUToTLTOh5O5rT6MhQvv3upN9evh63P3SHY_v33vtjtiy28y4QqHXoqNUGLTKqFqWVsum6FRlI1MGcpFT-3QM2vblg0ojaIN27BG1n1Nx4HfVJ-XveVFf86Ysv4dztEXSs0azpniraIF1S4oG8vdEUc9R3cy8UXTWl9d1MVF_eaivhq4JKk5_wfsZZeG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2833273971</pqid></control><display><type>article</type><title>Long-term Kinetics of Alpha-fetoprotein in Chronic Hepatitis C Patients Treated with Direct-acting Antivirals and Possible Predictive Role of AFP Response to Treatment on Development of Hepatocellular Carcinoma</title><source>Publicly Available Content (ProQuest)</source><creator>Ulaşoğlu, Celal ; Erkalma Şenateş, Banu ; Yapalı, Suna ; Dumanoğlu, Betül ; Enc, Feruze ; Çolak, Yaşar ; Şenateş, Ebubekir</creator><creatorcontrib>Ulaşoğlu, Celal ; Erkalma Şenateş, Banu ; Yapalı, Suna ; Dumanoğlu, Betül ; Enc, Feruze ; Çolak, Yaşar ; Şenateş, Ebubekir</creatorcontrib><description>Objectives: To evaluate the post-treatment upto fourth-year kinetics of alpha-fetoprotein (AFP) in patients with chronic hepatitis C (CHC) treated with direct-acting antiviral (DAA) drugs. Materials and Methods: In this retrospective, single-center study, 182 patients (124 female, 58 male) with CHC treated with DAA were included in the study. Biochemistry and AFP were recruited from the hospital database. The data at pre-treatment, 3rd and 48th month after the end of treatment were evaluated. Results: Of the 182 patients, mean age was 58±12 (28-76), and forty-nine (27%) had cirrhosis. At month 3, the average decline of AFP was 35.6% (0.4-97.0). Early decline of AFP &lt;8.7% was found to be a predictor for HCC development. Mean AFP was 7.7±9.2 ng/mL at pre-treatment and 3.8±2.7 at third month (p&lt;0.001). The decline persisted at 48th month (3.6±2.4 ng/mL). Conclusion: Early decline of AFP and persistence at fourth-year after DAA treatment was observed, except five cases developing HCC. Inadequate decline in AFP level found to be a possible predictor for HCC development. However, these results needs to be confirmed in large-scale multicenter cohorts. This study highlights the importance of AFP response to DAA treatment in identifying HCC risk, especially in patients with cirrhosis.</description><identifier>ISSN: 1307-9441</identifier><identifier>EISSN: 2147-2939</identifier><identifier>DOI: 10.4274/vhd.galenos.2021.2021-5-3</identifier><language>eng</language><publisher>Ankara: Galenos Publishing House</publisher><subject>Antiviral drugs ; Conflicts of interest ; Diabetes ; Ethics ; Females ; Genotype &amp; phenotype ; Hepatitis C ; Hypertension ; Laboratories ; Liver cancer ; Liver cirrhosis ; Risk factors ; Surveillance ; Ultrasonic imaging</subject><ispartof>Viral hepatit dergisi, 2021-08, Vol.27 (2), p.49-52</ispartof><rights>2021. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-8511-6146 ; 0000-0001-7686-0048 ; 0000-0002-2104-6783 ; 0000-0001-6069-230X ; 0000-0001-9758-7730 ; 0000-0002-5804-7552 ; 0000-0002-4320-2425</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2833273971/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2833273971?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590,75126</link.rule.ids></links><search><creatorcontrib>Ulaşoğlu, Celal</creatorcontrib><creatorcontrib>Erkalma Şenateş, Banu</creatorcontrib><creatorcontrib>Yapalı, Suna</creatorcontrib><creatorcontrib>Dumanoğlu, Betül</creatorcontrib><creatorcontrib>Enc, Feruze</creatorcontrib><creatorcontrib>Çolak, Yaşar</creatorcontrib><creatorcontrib>Şenateş, Ebubekir</creatorcontrib><title>Long-term Kinetics of Alpha-fetoprotein in Chronic Hepatitis C Patients Treated with Direct-acting Antivirals and Possible Predictive Role of AFP Response to Treatment on Development of Hepatocellular Carcinoma</title><title>Viral hepatit dergisi</title><description>Objectives: To evaluate the post-treatment upto fourth-year kinetics of alpha-fetoprotein (AFP) in patients with chronic hepatitis C (CHC) treated with direct-acting antiviral (DAA) drugs. Materials and Methods: In this retrospective, single-center study, 182 patients (124 female, 58 male) with CHC treated with DAA were included in the study. Biochemistry and AFP were recruited from the hospital database. The data at pre-treatment, 3rd and 48th month after the end of treatment were evaluated. Results: Of the 182 patients, mean age was 58±12 (28-76), and forty-nine (27%) had cirrhosis. At month 3, the average decline of AFP was 35.6% (0.4-97.0). Early decline of AFP &lt;8.7% was found to be a predictor for HCC development. Mean AFP was 7.7±9.2 ng/mL at pre-treatment and 3.8±2.7 at third month (p&lt;0.001). The decline persisted at 48th month (3.6±2.4 ng/mL). Conclusion: Early decline of AFP and persistence at fourth-year after DAA treatment was observed, except five cases developing HCC. Inadequate decline in AFP level found to be a possible predictor for HCC development. However, these results needs to be confirmed in large-scale multicenter cohorts. This study highlights the importance of AFP response to DAA treatment in identifying HCC risk, especially in patients with cirrhosis.</description><subject>Antiviral drugs</subject><subject>Conflicts of interest</subject><subject>Diabetes</subject><subject>Ethics</subject><subject>Females</subject><subject>Genotype &amp; phenotype</subject><subject>Hepatitis C</subject><subject>Hypertension</subject><subject>Laboratories</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Risk factors</subject><subject>Surveillance</subject><subject>Ultrasonic imaging</subject><issn>1307-9441</issn><issn>2147-2939</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNotUduK2zAQNaWFht39hyl9VmrdIvsxeLvd0kDDsn0WsjxOVBzJlZSU_c39oir1wjAXOMw5M6eqPtF6LZgSXy7HYX0wE_qQ1qxm9H8ikvB31YpRoQhrefu-WlFeK9IKQT9Wdym5vhZCbYRUclW97oI_kIzxBD-cx-xsgjDCdpqPhoyYwxxDRuehRHeMwTsLjzib7LJL0MG-dOhzgueIJuMAf10-wr2LaDMxNjt_gK3P7uKimRIYP8A-XDVMCPuIgyuQC8JTKPOV92EPT5jm4BNCDsvWUyGA4OEeLziFeRnHRUawOE3nyUToTLTOh5O5rT6MhQvv3upN9evh63P3SHY_v33vtjtiy28y4QqHXoqNUGLTKqFqWVsum6FRlI1MGcpFT-3QM2vblg0ojaIN27BG1n1Nx4HfVJ-XveVFf86Ysv4dztEXSs0azpniraIF1S4oG8vdEUc9R3cy8UXTWl9d1MVF_eaivhq4JKk5_wfsZZeG</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Ulaşoğlu, Celal</creator><creator>Erkalma Şenateş, Banu</creator><creator>Yapalı, Suna</creator><creator>Dumanoğlu, Betül</creator><creator>Enc, Feruze</creator><creator>Çolak, Yaşar</creator><creator>Şenateş, Ebubekir</creator><general>Galenos Publishing House</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><orcidid>https://orcid.org/0000-0002-8511-6146</orcidid><orcidid>https://orcid.org/0000-0001-7686-0048</orcidid><orcidid>https://orcid.org/0000-0002-2104-6783</orcidid><orcidid>https://orcid.org/0000-0001-6069-230X</orcidid><orcidid>https://orcid.org/0000-0001-9758-7730</orcidid><orcidid>https://orcid.org/0000-0002-5804-7552</orcidid><orcidid>https://orcid.org/0000-0002-4320-2425</orcidid></search><sort><creationdate>20210801</creationdate><title>Long-term Kinetics of Alpha-fetoprotein in Chronic Hepatitis C Patients Treated with Direct-acting Antivirals and Possible Predictive Role of AFP Response to Treatment on Development of Hepatocellular Carcinoma</title><author>Ulaşoğlu, Celal ; Erkalma Şenateş, Banu ; Yapalı, Suna ; Dumanoğlu, Betül ; Enc, Feruze ; Çolak, Yaşar ; Şenateş, Ebubekir</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c214t-37edb54647469747050c358d8712f27a134b1cdb2cc992de5a718262850b01fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiviral drugs</topic><topic>Conflicts of interest</topic><topic>Diabetes</topic><topic>Ethics</topic><topic>Females</topic><topic>Genotype &amp; phenotype</topic><topic>Hepatitis C</topic><topic>Hypertension</topic><topic>Laboratories</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Risk factors</topic><topic>Surveillance</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ulaşoğlu, Celal</creatorcontrib><creatorcontrib>Erkalma Şenateş, Banu</creatorcontrib><creatorcontrib>Yapalı, Suna</creatorcontrib><creatorcontrib>Dumanoğlu, Betül</creatorcontrib><creatorcontrib>Enc, Feruze</creatorcontrib><creatorcontrib>Çolak, Yaşar</creatorcontrib><creatorcontrib>Şenateş, Ebubekir</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Viral hepatit dergisi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ulaşoğlu, Celal</au><au>Erkalma Şenateş, Banu</au><au>Yapalı, Suna</au><au>Dumanoğlu, Betül</au><au>Enc, Feruze</au><au>Çolak, Yaşar</au><au>Şenateş, Ebubekir</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term Kinetics of Alpha-fetoprotein in Chronic Hepatitis C Patients Treated with Direct-acting Antivirals and Possible Predictive Role of AFP Response to Treatment on Development of Hepatocellular Carcinoma</atitle><jtitle>Viral hepatit dergisi</jtitle><date>2021-08-01</date><risdate>2021</risdate><volume>27</volume><issue>2</issue><spage>49</spage><epage>52</epage><pages>49-52</pages><issn>1307-9441</issn><eissn>2147-2939</eissn><abstract>Objectives: To evaluate the post-treatment upto fourth-year kinetics of alpha-fetoprotein (AFP) in patients with chronic hepatitis C (CHC) treated with direct-acting antiviral (DAA) drugs. Materials and Methods: In this retrospective, single-center study, 182 patients (124 female, 58 male) with CHC treated with DAA were included in the study. Biochemistry and AFP were recruited from the hospital database. The data at pre-treatment, 3rd and 48th month after the end of treatment were evaluated. Results: Of the 182 patients, mean age was 58±12 (28-76), and forty-nine (27%) had cirrhosis. At month 3, the average decline of AFP was 35.6% (0.4-97.0). Early decline of AFP &lt;8.7% was found to be a predictor for HCC development. Mean AFP was 7.7±9.2 ng/mL at pre-treatment and 3.8±2.7 at third month (p&lt;0.001). The decline persisted at 48th month (3.6±2.4 ng/mL). Conclusion: Early decline of AFP and persistence at fourth-year after DAA treatment was observed, except five cases developing HCC. Inadequate decline in AFP level found to be a possible predictor for HCC development. However, these results needs to be confirmed in large-scale multicenter cohorts. This study highlights the importance of AFP response to DAA treatment in identifying HCC risk, especially in patients with cirrhosis.</abstract><cop>Ankara</cop><pub>Galenos Publishing House</pub><doi>10.4274/vhd.galenos.2021.2021-5-3</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-8511-6146</orcidid><orcidid>https://orcid.org/0000-0001-7686-0048</orcidid><orcidid>https://orcid.org/0000-0002-2104-6783</orcidid><orcidid>https://orcid.org/0000-0001-6069-230X</orcidid><orcidid>https://orcid.org/0000-0001-9758-7730</orcidid><orcidid>https://orcid.org/0000-0002-5804-7552</orcidid><orcidid>https://orcid.org/0000-0002-4320-2425</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1307-9441
ispartof Viral hepatit dergisi, 2021-08, Vol.27 (2), p.49-52
issn 1307-9441
2147-2939
language eng
recordid cdi_proquest_journals_2833273971
source Publicly Available Content (ProQuest)
subjects Antiviral drugs
Conflicts of interest
Diabetes
Ethics
Females
Genotype & phenotype
Hepatitis C
Hypertension
Laboratories
Liver cancer
Liver cirrhosis
Risk factors
Surveillance
Ultrasonic imaging
title Long-term Kinetics of Alpha-fetoprotein in Chronic Hepatitis C Patients Treated with Direct-acting Antivirals and Possible Predictive Role of AFP Response to Treatment on Development of Hepatocellular Carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T03%3A19%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20Kinetics%20of%20Alpha-fetoprotein%20in%20Chronic%20Hepatitis%20C%20Patients%20Treated%20with%20Direct-acting%20Antivirals%20and%20Possible%20Predictive%20Role%20of%20AFP%20Response%20to%20Treatment%20on%20Development%20of%20Hepatocellular%20Carcinoma&rft.jtitle=Viral%20hepatit%20dergisi&rft.au=Ula%C5%9Fo%C4%9Flu,%20Celal&rft.date=2021-08-01&rft.volume=27&rft.issue=2&rft.spage=49&rft.epage=52&rft.pages=49-52&rft.issn=1307-9441&rft.eissn=2147-2939&rft_id=info:doi/10.4274/vhd.galenos.2021.2021-5-3&rft_dat=%3Cproquest_cross%3E2833273971%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c214t-37edb54647469747050c358d8712f27a134b1cdb2cc992de5a718262850b01fd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2833273971&rft_id=info:pmid/&rfr_iscdi=true